Psoriasis | Novartis | CAIN457ACA02 (PURE)
Pharmaceutical Company/Sponsor:
Novartis
Code:
CAIN457ACA02 (PURE)
Title:
A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)
Type:
Observational
Phase:
4
Condition/Disease:
Psoriasis
Intervention(s)/Treatment(s):
Drug: Secukinumab
Status:
Recruiting
Link for Additional Information:
